Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...
The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...
Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness.
The drug, nirsevimab, was effective against respiratory syncytial virus infections when used in the Yukon-Kuskokwim Delta, a ...
Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness, according to two studies published online Nov. 25 in Pediatrics. David W.
Newborns whose mothers have not received the RSV vaccine, should receive Nirsevimab between October and March. Public health leaders stress one of the best ways to reduce transmission of viruses is to ...
Nirsevimab (Beyfortus), an antibody targeting respiratory syncytial virus (RSV), is indicated for newborns and infants to prevent bronchiolitis. Available since September 2023, its widespread use ...
The drug, nirsevimab, was effective against respiratory syncytial virus infections when used in the Yukon-Kuskokwim Delta, a rural region known for high rates of that disease among infants ...
The researchers found that 45,693 outpatient visits, 15,866 emergency department visits, and 7571 hospitalizations among infants would be prevented each year by year-round maternal vaccination.